BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization.

The FDA has granted full approval for Novavax's COVID-19 vaccine, but with restrictions. Discover the details now.

The U.S. Food and Drug Administration (FDA) announced new regulatory guidelines for COVID-19 vaccine boosters on Tuesday, ...

In an article published in The New England Journal of Medicine titled “An Evidence-Based Approach to Covid-19 Vaccination” by ...